Lyell Immunopharma (LYEL) COO sells 1,236 shares for tax withholding

Rhea-AI Filing Summary

Lyell Immunopharma's Chief Operating Officer Stephen J. Hill reported an open-market sale of 1,236 shares of common stock on February 11, 2026. The shares were automatically sold to cover tax withholding obligations from the settlement of performance-based vested restricted stock units.

The sale was executed at a weighted average price of $23.39 per share, with individual trade prices ranging from $23.3939 to $24.7850 per share. Following this transaction, Hill directly beneficially owns 17,795 shares of Lyell Immunopharma common stock.

Insider Trade Summary

Net Seller: 1,236 shares ($28,910)

Net Sell 1 txn

Insider Hill Stephen J.

Role Chief Operating Officer

Sold 1,236 shs ($29K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,236	$23.39	$29K

Holdings After Transaction: Common Stock — 17,795 shares (Direct)

Footnotes (1)

1. Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units. The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hill Stephen J.

(Last) (First) (Middle)

C/O LYELL IMMUNOPHARMA, INC.

201 HASKINS WAY

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		S		1,236(1)	D	$23.39(2)	17,795	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units.

2. The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

	/s/ Mark Meltz, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lyell Immunopharma (LYEL) disclose in this Form 4?

Lyell Immunopharma disclosed that its Chief Operating Officer, Stephen J. Hill, sold 1,236 shares of common stock. The transaction was an open-market sale on February 11, 2026, primarily to cover tax withholding from vested performance-based restricted stock units.

Who is the insider involved in the latest Lyell Immunopharma (LYEL) Form 4 filing?

The insider is Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma. He is listed as an officer, not a director or 10% owner, and reported a sale of common stock while retaining a direct beneficial ownership position after the transaction.

How many Lyell Immunopharma (LYEL) shares did the COO sell and at what price?

Stephen J. Hill sold 1,236 shares of Lyell Immunopharma common stock. The weighted average sale price was $23.39 per share, with individual sales executed in a price range from $23.3939 to $24.7850 per share.

Why were Lyell Immunopharma (LYEL) shares sold by the COO in this transaction?

The shares were automatically sold to satisfy tax withholding obligations. The sale resulted from the settlement of performance-based vested restricted stock units, meaning the transaction was driven by tax requirements rather than a discretionary share sale decision.

How many Lyell Immunopharma (LYEL) shares does the COO own after the reported sale?

After the transaction, Chief Operating Officer Stephen J. Hill beneficially owns 17,795 shares of Lyell Immunopharma common stock. These shares are reported as directly held, reflecting his remaining equity position following the 1,236-share sale to cover tax withholding.

What type of transaction code is used in the Lyell Immunopharma (LYEL) Form 4?

The Form 4 uses transaction code "S", indicating a sale in an open-market or private transaction. Here it reflects an open-market sale of common stock executed to cover tax withholding tied to performance-based restricted stock unit vesting.